Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interpore Cross Steps Up Medtronic Sofamor Danek Spinal Screw Litigation

This article was originally published in The Gray Sheet

Executive Summary

Previous success in litigation brought against J&J/DePuy Acromed by Interpore Cross bodes well for the firm's ongoing variable locking polyaxial screw patent infringement lawsuit against Medtronic

You may also be interested in...



Interpore Cross v. Medtronic

Santa Ana, Calif. district court rules in favor of Interpore, stating that Medtronic Sofamor Danek infringed Synergy variable locking polyaxial screw patent 5,474,555 with screws sold under Sextant, Vertex, Legacy and other brands. Interpore expects to file for damages following a ruling on Medtronic's counterclaim that the patent is invalid. The counterclaim ruling is anticipated by July 12 and will be decided by the same judge (1"The Gray Sheet" May 12, 2003, p. 24)...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018364

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel